Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2022 Earnings Conference Call March 2, 2023 8:45 AM ET

Company Participants

Lisa Caperelli - VP of IR

William Collier - President and CEI

Michael Sofia - Chief Scientific Officer

David Hastings - CFO

Michael McElhaugh - COO

Conference Call Participants

Dennis Ding - Jefferies

Charles Moore - Baird

Thomas Yip - H.C. Wainwright

Keay Nakae - Chardan

Roy Buchanan - JMP Securities

Operator

Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Corporation Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call. At this time all participants are in a listen-only mode. After the speakers presentation there’ll be a question-and-answer session. [Operator Instructions]. Please be advised today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Lisa Caperelli. Please go ahead.

Lisa Caperelli

Thank you, Kevin. Good morning, everyone, and thank you for joining Arbutus' Fourth Quarter and Year-end 2022 Financial Results and Corporate Update Call. Joining me today from the Arbutus Executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with a corporate update, followed by Dr. Sofia who will provide an overview of our newly nominated coronavirus compound AB-343. Dave Hastings will then provide a review of the company's fourth quarter and year-end 2022 financial results. After our prepared remarks, we will open the call for Q&A.

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our annual report on Form 10-K to be filed later today and from time to time in our other documents filed with the SEC.

With that, I'll turn the call over to Bill Collier. Bill?

William Collier

Thank you, Lisa. Good morning, everyone, and thank you for joining us today. We appreciate your continued interest and support of Arbutus Biopharma.

This morning, we issued a press release with our fourth quarter and year-end 2022 financials, as well as an update on the significant progress we made last year in advancing our proprietary compounds, moving us closer to our goals of potentially achieving a functional cure for chronic HBV as well as a novel and superior treatment for corona.